mRNA vaccines utilise mRNA to generate a antigen protein within the cytosol of an eukaryote cell. Although they work well in animal models experience with these in man suggest low ability to induce immunity. They were first developed as a form of immunotherapy against some cancers, and then directed at virus surface proteins such as with the development of a mRNA-based vaccine encoding rabies virus glycoprotein (CV7201). Development suggests to date that injector devices may create better immunogenicity than the classic IM or s/c injection technique of other vaccines and the vaccine technology allows rapid development cycles and negligible risk of incorporation into the genome as with DNA vaccines or the one shot implication of viral vector vaccines.
- ↑ Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009 Jun; 32(5):498-507.(Print) (Link to article – subscription may be required.)
- ↑ Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. Journal for immunotherapy of cancer. 2015 ; 3:26.(Electronic-eCollection) (Link to article – subscription may be required.)
- ↑ Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet (London, England). 2017 Jul.(Print-Electronic) (Link to article – subscription may be required.)
- ↑ Warrell M. Is there a future for mRNAs as viral vaccines? Lancet (London, England). 2017 Jul.(Print-Electronic) (Link to article – subscription may be required.)